452 research outputs found
Hidden Quantum Gravity in 3d Feynman diagrams
In this work we show that 3d Feynman amplitudes of standard QFT in flat and
homogeneous space can be naturally expressed as expectation values of a
specific topological spin foam model. The main interest of the paper is to set
up a framework which gives a background independent perspective on usual field
theories and can also be applied in higher dimensions. We also show that this
Feynman graph spin foam model, which encodes the geometry of flat space-time,
can be purely expressed in terms of algebraic data associated with the Poincare
group. This spin foam model turns out to be the spin foam quantization of a BF
theory based on the Poincare group, and as such is related to a quantization of
3d gravity in the limit where the Newton constant G_N goes to 0. We investigate
the 4d case in a companion paper where the strategy proposed here leads to
similar results.Comment: 35 pages, 4 figures, some comments adde
Asymptotics of the Wigner 9j symbol
We present the asymptotic formula for the Wigner 9j-symbol, valid when all
quantum numbers are large, in the classically allowed region. As in the
Ponzano-Regge formula for the 6j-symbol, the action is expressed in terms of
lengths of edges and dihedral angles of a geometrical figure, but the angles
require care in definition. Rules are presented for converting spin networks
into the associated geometrical figures. The amplitude is expressed as the
determinant of a 2x2 matrix of Poisson brackets. The 9j-symbol possesses
caustics associated with the fold and elliptic and hyperbolic umbilic
catastrophes. The asymptotic formula obeys the exact symmetries of the
9j-symbol.Comment: 17 pages, 7 figure
Semiclassical Mechanics of the Wigner 6j-Symbol
The semiclassical mechanics of the Wigner 6j-symbol is examined from the
standpoint of WKB theory for multidimensional, integrable systems, to explore
the geometrical issues surrounding the Ponzano-Regge formula. The relations
among the methods of Roberts and others for deriving the Ponzano-Regge formula
are discussed, and a new approach, based on the recoupling of four angular
momenta, is presented. A generalization of the Yutsis-type of spin network is
developed for this purpose. Special attention is devoted to symplectic
reduction, the reduced phase space of the 6j-symbol (the 2-sphere of Kapovich
and Millson), and the reduction of Poisson bracket expressions for
semiclassical amplitudes. General principles for the semiclassical study of
arbitrary spin networks are laid down; some of these were used in our recent
derivation of the asymptotic formula for the Wigner 9j-symbol.Comment: 64 pages, 50 figure
Active Brownian Particles. From Individual to Collective Stochastic Dynamics
We review theoretical models of individual motility as well as collective
dynamics and pattern formation of active particles. We focus on simple models
of active dynamics with a particular emphasis on nonlinear and stochastic
dynamics of such self-propelled entities in the framework of statistical
mechanics. Examples of such active units in complex physico-chemical and
biological systems are chemically powered nano-rods, localized patterns in
reaction-diffusion system, motile cells or macroscopic animals. Based on the
description of individual motion of point-like active particles by stochastic
differential equations, we discuss different velocity-dependent friction
functions, the impact of various types of fluctuations and calculate
characteristic observables such as stationary velocity distributions or
diffusion coefficients. Finally, we consider not only the free and confined
individual active dynamics but also different types of interaction between
active particles. The resulting collective dynamical behavior of large
assemblies and aggregates of active units is discussed and an overview over
some recent results on spatiotemporal pattern formation in such systems is
given.Comment: 161 pages, Review, Eur Phys J Special-Topics, accepte
c-di-AMP Is a New Second Messenger in Staphylococcus aureus with a Role in Controlling Cell Size and Envelope Stress.
Published versio
Extending light WIMP searches to single scintillation photons in LUX
We present a novel analysis technique for liquid xenon time projection chambers that allows for a lower threshold by relying on events with a prompt scintillation signal consisting of single detected photons. The energy threshold of the LUX dark matter experiment is primarily determined by the smallest scintillation response detectable, which previously required a twofold coincidence signal in its photomultiplier arrays, enforced in data analysis. The technique presented here exploits the double photoelectron emission effect observed in some photomultiplier models at vacuum ultraviolet wavelengths. We demonstrate this analysis using an electron recoil calibration dataset and place new constraints on the spin-independent scattering cross section of weakly interacting massive particles (WIMPs) down to 2.5 GeV/c2 WIMP mass using the 2013 LUX dataset. This new technique is promising to enhance light WIMP and astrophysical neutrino searches in next-generation liquid xenon experiments
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
BACKGROUND:
Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival.
METHODS:
We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0–2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m2 intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544).
FINDINGS:
Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86–107) in the abiraterone trial and 72 months (61–74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8–86·9) in the abiraterone group versus 45·7 months (41·6–52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53–0·73]; p<0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9–81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3–59·0) in the standard of care group (HR 0·65 [0·55–0·77]; p<0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83–1·32]; pinteraction=0·71) or between-trial heterogeneity (I2 p=0·70). In the first 5 years of treatment, grade 3–5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (<1%) with standard of care in the abiraterone trial).
INTERPRETATION:
Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years.
FUNDING:
Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas
Background Determination for the LUX-ZEPLIN (LZ) Dark Matter Experiment
The LUX-ZEPLIN experiment recently reported limits on WIMP-nucleus
interactions from its initial science run, down to cm
for the spin-independent interaction of a 36 GeV/c WIMP at 90% confidence
level. In this paper, we present a comprehensive analysis of the backgrounds
important for this result and for other upcoming physics analyses, including
neutrinoless double-beta decay searches and effective field theory
interpretations of LUX-ZEPLIN data. We confirm that the in-situ determinations
of bulk and fixed radioactive backgrounds are consistent with expectations from
the ex-situ assays. The observed background rate after WIMP search criteria
were applied was events/keV/kg/day in the
low-energy region, approximately 60 times lower than the equivalent rate
reported by the LUX experiment.Comment: 25 pages, 15 figure
Breast cancer stem cells: implications for therapy of breast cancer
The concept of cancer stem cells responsible for tumour origin, maintenance, and resistance to treatment has gained prominence in the field of breast cancer research. The therapeutic targeting of these cells has the potential to eliminate residual disease and may become an important component of a multimodality treatment. Recent improvements in immunotherapy targeting of tumour-associated antigens have advanced the prospect of targeting breast cancer stem cells, an approach that might lead to more meaningful clinical remissions. Here, we review the role of stem cells in the healthy breast, the role of breast cancer stem cells in disease, and the potential to target these cells
- …